Teruo Sekimoto MD , Kazuhiro Fujiyoshi MD , Rika Kawakami MD , Anna Madra PhD , Takamasa Tanaka MD , Doosup Shin MD , Eric H. Wolff , Tatsuya Shiraki MD , Takafumi Nakayama MD , Tomoyo Hamana MD , Renu Virmani MD , Ziad A. Ali MD , Aloke V. Finn MD
{"title":"Comparison of Vascular Injury From Intravascular Lithotripsy, Cutting, or Ultra-High-Pressure Balloons During Coronary Calcium Modification","authors":"Teruo Sekimoto MD , Kazuhiro Fujiyoshi MD , Rika Kawakami MD , Anna Madra PhD , Takamasa Tanaka MD , Doosup Shin MD , Eric H. Wolff , Tatsuya Shiraki MD , Takafumi Nakayama MD , Tomoyo Hamana MD , Renu Virmani MD , Ziad A. Ali MD , Aloke V. Finn MD","doi":"10.1016/j.jcin.2025.06.035","DOIUrl":"10.1016/j.jcin.2025.06.035","url":null,"abstract":"<div><h3>Background</h3><div>Effective modification of heavily calcified coronary lesions is critical for successful percutaneous coronary intervention (PCI). Intravascular lithotripsy (IVL), cutting balloons (CBs), and ultra-high-pressure balloons (UHBs) are used commonly, yet data comparing their effectiveness and safety for calcified lesion modification remain unavailable.</div></div><div><h3>Objectives</h3><div>The aim of this study was to compare the effects of IVL, a CB, and a UHB on calcified coronary lesions in human cadaveric arteries, focusing on calcium fracture formation and vascular injury.</div></div><div><h3>Methods</h3><div>Seventeen calcified lesions from 6 cadavers were randomized to treatment with IVL (n = 5), the CB (n = 6), or the UHB (n = 6). Pre- and post-treatment optical coherence tomography, micro–computed tomography (CT), and histology were coregistered to evaluate calcium fractures and medial injury.</div></div><div><h3>Results</h3><div>Fractures confirmed by micro-CT and histology were observed in 80% of IVL-treated lesions, 66.7% treated with the CB, and 33.3% treated with the UHB (<em>P</em> = 0.350). Medial injury occurred significantly less frequently with IVL (20.0%) compared with the CB (83.3%) and the UHB (100%) (<em>P</em> = 0.012). In histologic sections with a calcium arc of ≥180°, IVL induced fractures in 100% of sections, all without medial injury, while the CB and UHB caused fractures without medial injury in 16.7% and 20.0% of sections, respectively (<em>P</em> = 0.007). For calcium arcs <180°, IVL produced fractures in 57.1% of sections, all without medial injury, compared with the CB (11.1% without medial injury) and UHB (0% without medial injury) (<em>P</em> = 0.008).</div></div><div><h3>Conclusions</h3><div>IVL effectively modifies calcified lesions with less medial vascular injury compared with a CB and a UHB.</div></div>","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"18 17","pages":"Pages 2093-2104"},"PeriodicalIF":11.4,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145019338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Aspirin vs Clopidogrel 1 Month After Acute Coronary Syndrome With High-Bleeding Risk or ST-Segment Elevation","authors":"Yuki Obayashi MD , Masahiro Natsuaki MD , Hirotoshi Watanabe MD , Takeshi Morimoto MD , Ko Yamamoto MD , Ryusuke Nishikawa MD , Tomoya Kimura MD , Kenji Ando MD , Satoru Suwa MD , Tsuyoshi Isawa MD , Hiroyuki Takenaka MD , Tetsuya Ishikawa MD , Hideo Tokuyama MD , Hiroki Sakamoto MD , Takanari Fujita MD , Mamoru Nanasato MD , Hideki Okayama MD , Tenjin Nishikura MD , Hidekuni Kirigaya MD , Koji Nishida MD , Takeshi Kimura MD","doi":"10.1016/j.jcin.2025.03.029","DOIUrl":"10.1016/j.jcin.2025.03.029","url":null,"abstract":"<div><h3>Background</h3><div>High bleeding<span> risk (HBR) and acute coronary syndrome<span> (ACS) subtypes (ST-segment elevation myocardial infarction [STEMI] and non–ST-segment elevation ACS [NSTE-ACS]) might be key determinants of appropriate antiplatelet strategies.</span></span></div></div><div><h3>Objectives</h3><div>The aim of this study was to investigate the effects of aspirin<span> versus clopidogrel within 1 year after percutaneous coronary intervention in patients with ACS, on the basis of HBR or non-HBR and STEMI or NSTE-ACS.</span></div></div><div><h3>Methods</h3><div>Patients with ACS in the STOPDAPT-3 (Short and Optimal Duration of Dual Antiplatelet Therapy-3) trial were included. Aspirin and clopidogrel monotherapy<span><span> were compared beyond 30 days and up to 1 year in the prespecified subgroups stratified by HBR or non-HBR and STEMI or NSTE-ACS. The coprimary cardiovascular endpoint was a composite of cardiovascular death, myocardial infarction, definite stent thrombosis, or </span>ischemic stroke; the coprimary bleeding endpoint was major bleeding (Bleeding Academic Research Consortium type 3 or 5).</span></div></div><div><h3>Results</h3><div>Among 4,353 patients, 1,711 had HBR and 2,457 had STEMI. Throughout the 335-day follow-up period, the crude HRs for aspirin compared with clopidogrel were not statistically significant for cardiovascular endpoints in both the HBR or non-HBR (HR: 0.89 [95% CI: 0.61-1.30] and HR: 1.08 [95% CI: 0.61-1.90]; <em>P</em> for interaction = 0.59) and STEMI or NSTE-ACS (HR: 1.01 [95% CI: 0.68-1.50] and HR: 0.81 [95% CI: 0.48-1.37]; <em>P</em> for interaction = 0.51) subgroups. Similarly, the HRs for bleeding endpoints were not significant in both the HBR or non-HBR (HR: 0.73 [95% CI: 0.40-1.33] and HR: 0.71 [95% CI: 0.23-2.24]; <em>P</em> for interaction = 0.97) and STEMI or NSTE-ACS (HR: 0.96 [95% CI: 0.46-2.01] and HR: 0.53 [95% CI: 0.24-1.17]; <em>P</em> for interaction = 0.28) subgroups.</div></div><div><h3>Conclusions</h3><div>In patients with ACS, aspirin and clopidogrel demonstrated comparable effects on both cardiovascular and bleeding outcomes beyond 1 month and up to 1 year after percutaneous coronary intervention, irrespective of HBR or non-HBR and STEMI or NSTE-ACS. (Short and Optimal Duration of Dual Antiplatelet Therapy-3 Study [STOPDAPT-3]; <span><span>NCT04609111</span><svg><path></path></svg></span>)</div></div>","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"18 17","pages":"Pages 2120-2135"},"PeriodicalIF":11.4,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144234128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Antiplatelet Monotherapy After Short DAPT in ACS","authors":"Antonio Greco MD, PhD","doi":"10.1016/j.jcin.2025.04.042","DOIUrl":"10.1016/j.jcin.2025.04.042","url":null,"abstract":"","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"18 17","pages":"Pages 2136-2139"},"PeriodicalIF":11.4,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144234127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aish Sinha PhD, Haseeb Rahman PhD, Holly P. Morgan PhD, Kalpa De Silva PhD, Matthew E. Li Kam Wa MBBS, Matthew Ryan PhD, Ozan M. Demir PhD, Saad Ezad MBBS, Howard Ellis BSc, Divaka Perera MD
{"title":"Antianginal Therapy in Patients With Impaired Coronary Flow Reserve but Normal Minimal Microvascular Resistance","authors":"Aish Sinha PhD, Haseeb Rahman PhD, Holly P. Morgan PhD, Kalpa De Silva PhD, Matthew E. Li Kam Wa MBBS, Matthew Ryan PhD, Ozan M. Demir PhD, Saad Ezad MBBS, Howard Ellis BSc, Divaka Perera MD","doi":"10.1016/j.jcin.2025.06.033","DOIUrl":"10.1016/j.jcin.2025.06.033","url":null,"abstract":"","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"18 17","pages":"Pages 2189-2191"},"PeriodicalIF":11.4,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144794478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}